









市场行情
/
股票
/
nasdaq-amrn
/

Amarin Corporation PLC

AMRN

13.815USD

+0.215+1.58%

交易中（美东）报价延迟15分钟

287.33M总市值

亏损市盈率 TTM



Amarin Corporation PLC

13.815

+0.215+1.58%

概览公司财务分析

概览

公司

财务

分析

关于 Amarin Corporation PLC 公司

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Amarin Corporation PLC简介



公司代码AMRN

公司名称Amarin Corporation PLC

上市日期Apr 01, 1993

CEOBerg (Aaron D)

员工数量275

证券类型Depository Receipt

年结日Apr 01

公司地址WeWork One Central Plaza Dame Street

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Ireland

邮编D02 K7K5

电话35316699020

网址https://amarincorp.com/

公司代码AMRN

上市日期Apr 01, 1993

CEOBerg (Aaron D)

Amarin Corporation PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

Ms. Patrice Bonfiglio

Non-Executive Independent Director

Mr. Louis Sterling, III

Non-Executive Independent Director

Mr. Peter Fishman

Chief Financial Officer

Dr. Stephen B. (Steven) Ketchum, Ph.D.

President - Research and Development, Executive Vice President, Chief Scientific Officer

Mr. Aaron D. Berg

President, Chief Executive Officer, Director

Mr. Keith L. Horn

Non-Executive Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

Ms. Patrice Bonfiglio

Non-Executive Independent Director

Mr. Louis Sterling, III

Non-Executive Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

2.20%

Morgan Stanley & Co. LLC

1.21%

Eversept Partners, LP

0.80%

其他

87.04%

持股股东

占比

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

2.20%

Morgan Stanley & Co. LLC

1.21%

Eversept Partners, LP

0.80%

其他

87.04%

股东类型

持股股东

占比

Hedge Fund

12.07%

Investment Advisor/Hedge Fund

2.95%

Investment Advisor

2.79%

Research Firm

1.93%

Individual Investor

0.99%

Pension Fund

0.35%

Family Office

0.24%

其他

78.69%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

291

4.18M

22.49%

+4.06K

2025Q3

314

4.20M

24.13%

+467.66K

2025Q2

330

3.80M

23.58%

+94.36K

2025Q1

338

3.76M

23.88%

-1.19M

2024Q4

355

3.75M

23.57%

+236.09K

2024Q3

360

3.51M

29.65%

-554.68K

2024Q2

386

4.06M

34.43%

-548.92K

2024Q1

399

4.62M

36.64%

-2.90M

2023Q4

416

4.89M

38.80%

+197.93K

2023Q3

435

4.67M

42.33%

-650.41K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Sarissa Capital Management, L.P.

1.24M

6.01%

-4.00

-0.00%

Jun 30, 2025

Kynam Capital Management LP

576.11K

2.79%

-44.62K

-7.19%

Jun 30, 2025

Acadian Asset Management LLC

241.05K

1.17%

+51.47K

+27.15%

Jun 30, 2025

Morgan Stanley & Co. LLC

147.27K

0.71%

+31.23K

+26.91%

Jun 30, 2025

Eversept Partners, LP

167.28K

0.81%

-2.68K

-1.58%

Jun 30, 2025

Millennium Management LLC

45.24K

0.22%

+44.25K

+4470.10%

Jun 30, 2025

Citadel Advisors LLC

45.46K

0.22%

+45.46K

Jun 30, 2025

SCP Investment, LP

125.00K

0.6%

Jun 30, 2025

BNP Paribas Securities Corp. North America

75.94K

0.37%

+4.35K

+6.07%

Jun 30, 2025

Longitude (Cayman) Ltd

81.00K

0.39%

-37.50K

-31.65%

Dec 31, 2024

持股ETF



更新时间: 12月6日周六

机构名称

占比

ProShares Ultra Nasdaq Biotechnology

0.04%

Invesco Nasdaq Biotechnology ETF

0.03%

SPDR S&P International Small Cap ETF

0.02%

Global X Aging Population ETF

ActivePassive International Equity ETF

Invesco NASDAQ Future Gen 200 ETF

SPDR Portfolio Developed World ex-US ETF

ProShares Ultra Nasdaq Biotechnology

占比0.04%

Invesco Nasdaq Biotechnology ETF

占比0.03%

SPDR S&P International Small Cap ETF

占比0.02%

Global X Aging Population ETF

占比0%

ActivePassive International Equity ETF

占比0%

Invesco NASDAQ Future Gen 200 ETF

占比0%

SPDR Portfolio Developed World ex-US ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Mar 12, 2025

Merger

20→1

Mar 12, 2025

Merger

20→1

公告日期

类型

比率

Mar 12, 2025

Merger

20→1

Mar 12, 2025

Merger

20→1

常见问题

Amarin Corporation PLC的前五大股东是谁？



Amarin Corporation PLC 的前五大股东如下：
Sarissa Capital Management, L.P.持有股份：1.24M，占总股份比例：6.01%。
Kynam Capital Management LP持有股份：576.11K，占总股份比例：2.79%。
Acadian Asset Management LLC持有股份：241.05K，占总股份比例：1.17%。
Morgan Stanley & Co. LLC持有股份：147.27K，占总股份比例：0.71%。
Eversept Partners, LP持有股份：167.28K，占总股份比例：0.81%。